Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of VEGF polymorphisms and response to anti-VEGF therapy in neovascular age-related macular degeneration
2007-004487-53Phase 4Active
- Sponsor
- Azienda Ospedaliero-Universitaria Pisana
- Start
- Oct 2007
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of pegaptanib sodium and ranibizumab in exudative macular degeneration (5 arms), sponsored by Azienda Ospedaliero-Universitaria Pisana. Primary endpoints: Genetic analysis of VEGF polymorphisms and Statistical correlation analysis. Started Oct 2007; status: active.
02
Drugs
pegaptanib sodiumranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2007-004487-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004487-53.